US formally loses measles elimination status; 97% of cases occur in unvaccinated populations
Canada's measles outbreak illustrates: even with high overall vaccination rates, a single wedding can trigger nearly 2,400 cases in a low-vaccination community. America's problem is society-wide unvaccination spreading unchecked, with case curves showing no plateau.
The video won't play here. Listen to the audio instead:
The argument · tap a timestamp to hear it
The US has lost its measles elimination status
During the episode's recording, the American Society of Tropical Medicine and Hygiene conference discussed whether the US retained measles elimination status. Griffin was direct in his assessment: the data are clear—measles has been circulating continuously on US soil for over a year and is endemic. The US will lose this status. This constitutes a 'legacy-defining' decision, distinguishing his tenure as health secretary.
— Daniel GriffinInjecting flu vaccine directly into melanomas reverses tumor immune escape
A phase 1 trial gave standard intramuscular flu vaccine to 18 melanoma patients, then added two booster injections directly into the tumor. Pathology analysis showed 79% of samples had increased tumor-infiltrating lymphocytes; nearly 40% showed tumor regression, including 3 cases with complete pathologic response. Plasma cytokines IL-15 and GM-CSF increased significantly; the TH1/Treg ratio rose 1.5-fold; myeloid-derived suppressor cells decreased 70%; exhausted CD4 T cells decreased 65%. This attempted to directly reverse the tumor's immune escape mechanisms, based on findings from mouse models.
— Daniel GriffinPrimary dengue infection is equally likely to cause death
A woman who contracted dengue from a mosquito bite while walking in Florida died—the only death in the local outbreak. Griffin corrected a common misconception: the public widely believes severe dengue cases mainly result from antibody-dependent enhancement (secondary infection with a different serotype), but globally, dengue deaths occur mostly in children, and one-quarter of travelers hospitalized with dengue are on primary infection. Primary infection is equally likely to be fatal. The US currently has no approved dengue vaccine.
— Daniel GriffinExpanding vaccine use without proven efficacy undermines trial integrity
The Democratic Republic of Congo Ebola outbreak has exceeded 11,000 cases and 5,358 confirmed deaths—the second-largest and fastest-growing on record. Médecins Sans Frontières urged WHO to lift research-use restrictions on Ervebo and expand access widely. Griffin opposed this directly. The vaccine's efficacy has not been proven; now is the moment to verify it through clinical trials, not to deploy it at scale while uncertain of its effect. He also noted that the Congo's true shortage is contact-tracing personnel and resources, not vaccine.
— Daniel GriffinHigh vaccination rates elsewhere contained Canada's measles outbreak
Ontario achieved measles elimination in 1998; only 101 cases occurred between 2013 and 2023. An October 2024 exposure following a New Brunswick wedding triggered a 49-week outbreak with 2,377 cumulative cases. In November 2025, the Pan American Health Organization formally withdrew Canada's measles elimination status. Over 90% of cases concentrated in one community with chronically low vaccination; 97% were unvaccinated; three-quarters were under 19; there were 10 cases of congenital measles and 1 death. The key difference: the outbreak was contained by the surrounding population with over 95% vaccination rates and did not spread into the general population—entirely unlike America's society-wide unvaccination, driven by RFK Jr.-promoted vaccine skepticism.
— Daniel GriffinVaccines prevent severe disease, not infection itself
Responding to listeners' skepticism about mRNA-1345's '60% prevention of infection' against RSV, Griffin clarified that this figure measures symptomatic infection, not blocking the virus's initial replication on mucous membranes—vaccines cannot achieve that. He cited a past CDC slogan to summarize a vaccine's true effect: turn the wild into mild. The trial showed 81.8% protection against RSV-related hospitalization.
— Daniel GriffinT cell memory outlasts antibody response in vaccinated children
A longitudinal study in Montreal of children aged 3 to 14 found that one month after the second vaccine dose, anti-RBD IgG averaged 1,374 BAU/ml. By six months, levels had declined 856 units, essentially returning to baseline. T cell responses, however, showed nearly no significant decline over 12 months. This mechanism directly informed subsequent advice on whether a child with high fever and vomiting after injection should receive yearly vaccinations. Parents can weigh: antibody protection is short-lived; T cell protection is more durable.
— Daniel GriffinIn their own words · checked verbatim
Do you think we should expand the use of the Ervebo? We got to find out if it works. I think that's a huge problem. We don't even know if it works.
Daniel Griffin21:04
They're doing a good job in Canada in the general population because they don't have RFK Jr. to tell people that they shouldn't get vaccinated, right?
Daniel Griffin28:23
folks, it does contradict what RFK Jr. says, but ignore him because he doesn't know what he's talking about.
Daniel Griffin34:47
the biggest things that vaccines do, what do vaccines actually do, they, they prevent disease. The whole idea that somehow, as soon as the virus gets onto the mucosa and starts to replicate, it can't block that initial replication.
Daniel Griffin42:03
they turned the wild into mild, yes, exactly. And that was great. That was perfect. That's what vaccines do. They turn wild into mild.
Daniel Griffin43:05
if you go on the social media, they'll find the one study from Canada, you know, sometime where, you know, it failed to reach statistical significance, which in their world means it doesn't work, but that's not true.
Daniel Griffin52:28
Figures
| Democratic Republic of Congo Ebola cumulative cases | ~11,021 | 21:04 |
| Democratic Republic of Congo Ebola cumulative deaths | 5,358 | 21:04 |
| US this season influenza deaths in children | 3 (over 200 last season) | 36:48 |
| Canada Ontario measles outbreak cumulative cases | 2,377 spanning 49 weeks | 26:20 |
| Canada measles outbreak unvaccinated rate | ~90% | 26:20 |
| mRNA-1345 protection against RSV-related hospitalization | 81.8% | 41:03 |
| US this season measles cumulative cases | 5,400 with 10 deaths | 24:11 |
| Child COVID vaccine anti-RBD IgG peak and 6-month decline | 1,374 BAU/ml at 1 month; 856 BAU/ml decline by 6 months | 46:09 |
| Flu vaccine intralesional injection melanoma complete response rate | 3 of 18 | 8:35 |
Glossary
- vaccine-derived poliovirus
- Live vaccine strain that regains virulence and circulates in low-vaccination populations.
- antibody-dependent enhancement
- Antibodies to one dengue serotype enhance infection by another, worsening disease.
- BAU (binding antibody unit)
- WHO-standardized unit for comparing antibody levels across laboratories.
- turn the wild into mild
- Vaccine effect: reducing disease severity rather than preventing infection.
How to listen
Clinicians and parents tracking annual vaccination guidelines; public health practitioners tracking measles, Ebola, and dengue outbreaks.
The opening chat about Patrick Stewart and animal husbandry ethics (before 0:19:00) can be skipped.